Dyspepsia Market Size was valued at USD 9.96 Billion in 2023. The Global Dyspepsia industry is projected to grow from USD 18.23 Billion in 2024 to USD 16.32 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.89% during the forecast period (2024 - 2032). Dyspepsia is a chronic medical condition, that causes discomfort in the upper abdomen of the patient due to indigestion. The gastrointestinal organs, the stomach and the small intestine (sometimes the esophagus), do not function normally. Gastrointestinal causes of dyspepsia are gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced blood flow in the intestine (intestinal ischemia). Nongastrointestinal causes are diabetes, thyroid disease, kidney disease and consumption of drugs like nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen), antibiotics and others. Dyspepsia is also caused due to overeating, smoking and extreme consumption of alcohol. The increasing prevalence of digestive diseases is the key factor for the market to grow. According to the Centers for Disease Control and Prevention in 2016, 14.7 million people in the US suffered from digestive ulcers. Such a high prevalence of digestive diseases enhances the market growth during the forecast period. Other factors like growing caffeine intake, increasing alcohol consumption, rising prevalence of diabetes, increasing incidences of thyroid diseases and stomach cancer, robust R&D activities to develop new drugs and advancement in diagnosis and treatment technologies is driving the growth of the market.
However, factors such as expensive diagnosis test and intense competition among the major market players to gain maximum market share are expected to restrict the market growth during the forecast period.
The largest Romanian producer of gemotherapy extracts and also the only local producer of homeopathic medicines, part of the Europlant group, PlantExtrakt, declares it's launching VerdioGast-a, a natural product for digestion with triple action in April 2024. It is thus an alternative herbal to existing consumption habits in a market that is valued at around 30 million euros. In this regard, the company forecasts that the new product will acquire about 3% of the market value for the profile over the next five years. VerdioGast indicates a threefold impact on stomach function as well as pancreas and liver state, which distinguishes it from other brands on the market, including assisting in the breakdown of food substances within the gut, relieving bloating sensation within the abdomen while ensuring proper functioning of gall bladder and liver. There are no chemicals made synthetically or genetically modified organisms (GMOs) inside because this item is composed exclusively of herbs without any traces of animal pancreatin or bile.
According to an exchange filing by Sun Pharmaceutical Industries Ltd., results from two phase I studies evaluating tolerability, safety, pharmacodynamics, and pharmacokinetics were released this Saturday regarding GL0034 — a novel long‐acting GLP‐1 receptor agonist — in non-diabetic obese adults and non-obese ones. The data would be highlighted in poster presentations at ADA’s (American Diabetes Association’s) 83rd Scientific Sessions held between June 23-26th, 2023, in San Diego, CA.
Astellas Pharma Inc. said on July 20th that the U.S. Food and Drug Administration (FDA) had accepted for priority review its Biologics License Application (BLA) regarding zolbetuximab. Thus, if approved, it would be the first CLDN18.2 targeted therapy in the U.S. for these patients. The Prescription Drug User Fee Act (PDUFA) allows the FDA to complete its review of such applications by January 12, 2024. With this regard, a novel initiative known as Real-Time Oncology Review (RTOR) was initiated by the FDA to identify better ways of reviewing safe and effective treatments and accessing them quickly for patients needing them badly; hence, it should be completed by then.
Segmentation
The global dyspepsia market is segmented on the basis of diagnosis, treatment, and end-user. The dyspepsia market, by diagnosis, is sub-segmented into blood tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others. On the basis of treatment, the market is categorized into antacids, antibiotics, h2 blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies and others. Antacids are further sub-segmented into calcium carbonate, loperamide, simethicone, sodium bicarbonate and others. Antibiotics further sub-segmented into amoxicillin, clarithromycin, metronidazole, and others. H2 blockers are further categorized into cimetidine, famotidine, nizatidine, ranitidine, and others. Proton pump inhibitors (PPIs) is further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics are categorized into bethanechol and metoclopramide. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, pharmacies, diagnostic centers and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the U.S. and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the U.K., Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key Players
Global Dyspepsia Market Share (%), by Region, 2017
Sources: United European Gastroenterology, Cancer Research, the Centers for Disease Control and Prevention
The dyspepsia market is dominated by North America owing to rising prevalence of ulcerative colitis.
Ulcerative Colitis causes inflammation of the digestive tract which may lead to dyspepsia. According to the Centers for Disease Control and Prevention in 2015, 3 million people suffered from ulcerative colitis. Also, the increased adoption of technologically advanced devices and the high amount of healthcare expenditure drives the market growth in this region.
It is estimated that Europe stood second in the global dyspepsia market. Thus, increasing prevalence of chronic digestive disease in Europe contributes to market growth. According to the United European Gastroenterology report published in 2018, 365,000 deaths in Europe were due to digestive cancers. Also, rising healthcare expenditure and R&D activities are driving the growth of this market in Europe.
Asia-Pacific was projected to be the fastest growing region for the global dyspepsia market. Key factors such as rising number of patient population, increase in the adoption of minimally invasive surgeries, and rapid rise in endoscopy for the diagnosis and treatment of digestive diseases, influences the market in this region. Also, the rising medical tourism in countries like Malaysia, India, and Thailand drives market growth in this region.
The Middle East and Africa holds the least share of the global dyspepsia market due to the presence of stringent government policies and poor economies. However, increasing investment by private market players and growing government initiatives in this region can boost the market growth.
Market Segmentation and Key Market Players
Global Dyspepsia Market, by Diagnosis
Global Dyspepsia Market, by Treatment
Global Dyspepsia Market, by End-User
Global Dyspepsia Market, by Region
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 16.32 Billion |
| CAGR | 4.89% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Application, And End-User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | AstraZeneca, GlaxoSmithKline, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Salix Pharmaceuticals, Bayer AG, Boehringer Ingelheim GmbH, Sanofi, Allergan Plc, and others. |
| Key Market Opportunities | Research & Development |
| Key Market Drivers | · Rising prevalence of diabetes · Increasing incidences of thyroid diseases and stomach cancer · Robust R&D activities to develop new drugs · Advancement in diagnosis and treatment technologies |
Dyspepsia Market Highlights:
Frequently Asked Questions (FAQ) :
The dyspepsia market would be hindered by costly diagnostic procedures.
The leading region would be the Americas for the dyspepsia market.
End users profiled for dyspepsia market are ambulatory surgical centers, hospitals & clinics, diagnostic centers, pharmacies, and others.
The diagnosis-based treatments are breath tests, blood tests, endoscopy, stool tests, CT scans, X-rays, and others.
The treatment-based studies for dyspepsia market include antibiotics, antacids, proton pump inhibitors (PPIs), h2 blockers, psychological therapies, prokinetics, and others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
